See the DrugPatentWatch profile for Nplate
What “data exclusivity” means for Nplate
Nplate (romiplostim) is a medicine with regulatory protection that can include data exclusivity—time-limited protection that prevents other applicants from relying on the originator’s clinical trial data for approval in the same jurisdiction. Exactly how long that protection lasts depends on the regulator (for example, the EU vs. the US) and on the product’s approval and any later granted extensions.
How long is Nplate’s data exclusivity in the EU?
In the European Union, medicines approved through the centralised procedure generally benefit from regulatory periods that include a data-protection term for certain dossier elements. The practical effect is that, for a set number of years from approval, other sponsors typically cannot use the originator’s clinical trial data to support an application, unless they meet specific legal exceptions (such as consent, a link to protected data, or other qualifying conditions).
If you want the specific end date for Nplate, I need the approval country/region you mean (most people ask this as “EU” or “US”), because the duration and trigger date differ.
What about the US—does Nplate have data exclusivity there?
In the US, “data exclusivity” is often discussed alongside marketing exclusivity concepts that are set by the FDA framework. The exact protection window for a specific product depends on the pathway used at approval and whether it was a new drug application vs. a biologics license application, plus any extensions tied to new approvals or supplemental applications.
Does Nplate’s exclusivity differ from patent protection?
Yes. Data exclusivity and patent protection are separate layers:
- Data exclusivity limits who can rely on originator clinical data for regulatory approval.
- Patents can still block manufacturing/marketing even after data exclusivity ends.
So the ability for competitors to launch often depends on whether they can obtain approval without using protected data and whether any patents are still in force.
Does a new indication or formulation extend Nplate exclusivity?
Often, yes in principle. If an originator gets regulatory approval for a new indication or a qualifying change, some jurisdictions can grant additional periods of protection (the details are specific to the jurisdiction and the type of update). That can change when generic/biosimilar-type applicants can enter, even if the original approval is earlier.
Can competitors enter before data exclusivity ends?
Usually only in limited ways. Competitors may be able to:
- Seek approval in a way that does not rely on protected clinical data (jurisdiction-specific),
- Launch outside the scope of the protected indications,
- Or enter when the exclusivity period expires.
The feasibility depends on how the law treats reliance on existing data and on any other ongoing protections (like patents).
What I need from you to give the exact “data exclusivity” timeline
Tell me which jurisdiction you mean:
1) European Union (EMA) or specific EU country?
2) United States (FDA)?
And if you care about a specific trigger, tell me the context:
- original approval exclusivity, or
- extensions after a new indication/supplement.
With that, I can pin down the protection period and the likely earliest entry point based on data exclusivity alone (separate from patents).
Sources
I don’t have any source material to cite in this chat. If you paste a link (EMA/FDA label, EPAR/PL/assessment report, or a listing that mentions Nplate exclusivity), I’ll extract the exact duration and end date from it.